Park Linda 4

What Happened

• Linda Park, a director of BioLargo, Inc. (BLGO), was granted a stock option covering 115,741 underlying shares on 2026-03-31. The option was issued as payment for $18,750 in board fees under the issuer's 2024 Equity Incentive Plan. The filing lists the transaction as a derivative award (code A); no exercise price or fair-market value per share is provided in the Form 4.

Key Details

• Transaction date: 2026-03-31; Form 4 filed: 2026-04-01 (timely).
• Award type: Option grant (derivative) for 115,741 shares; transaction coded as A (award/grant).
• Cash equivalent: $18,750 in fees were paid via this option grant (per footnote).
• Exercise price / per-share value: Not disclosed in the filing; the number of option shares equals the fees due divided by the option’s exercise price (footnote).
• Shares owned after transaction: Not reported in the provided filing details.
• Footnote: The option was issued in lieu of fees owed to the reporting person for board services under BioLargo’s 2024 Equity Incentive Plan.

Context

• This was a compensation grant, not an open-market purchase or sale. Such option grants are commonly used to pay director fees and do not by themselves indicate the director bought or sold company stock. If and when the option is exercised (and whether shares are held or sold), that would be reported separately.